IL2 and neoplasm: Analysis of the ID8 OC model revealed a similar trend as in the OC patients whereby animals receiving ASA, low-dose IL-2, OCDC, anti-VEGF antibody (Bev), and Cy (Group C) demonstrated prolonged survival and reduced tumor burden.